| May 29 | 2020 |
AVEO Oncology Announces Phase 1b/2 DEDUCTIVE Study of FOTIVDA® (tivozanib) in Combination with IMFINZI® (durvalumab) in Previously Untreated Metastatic Hepatocellular Carcinoma Advances to Phase 2 |
| May 29 | 2020 |
AVEO Oncology Announces TIVO-3 Final Overall Survival Results Featured at ASCO 2020 Virtual Scientific Program and Submitted to U.S. FDA as Part of NDA Filing |
| May 27 | 2020 |
AVEO Announces Change to Virtual Annual Meeting of Stockholders |
| Apr 30 | 2020 |
AVEO Oncology Reports First Quarter 2020 Financial Results and Provides Business Update |
| Apr 29 | 2020 |
AVEO Oncology to Present Final Overall Survival Analysis from the Phase 3 TIVO-3 Trial of Tivozanib in Renal Cell Carcinoma at the ASCO 2020 Virtual Scientific Program |
| Mar 31 | 2020 |
AVEO Oncology Announces Submission of New Drug Application to U.S. FDA for Tivozanib in Patients with Relapsed or Refractory Renal Cell Carcinoma |
| Mar 27 | 2020 |
AVEO Oncology and Biodesix to Discontinue CyFi-2 Study of Ficlatuzumab in Relapsed and Refractory AML in Response to Public Health Crisis |
| Mar 16 | 2020 |
AVEO Oncology Reports Full Year 2019 Financial Results and Provides Business Update |
| Feb 19 | 2020 |
AVEO Announces Effectiveness of 1-for-10 Reverse Stock Split |
| Feb 12 | 2020 |
AVEO Oncology Announces Publication of Phase 1b/2 Study of Tivozanib in Advanced, Inoperable Liver Cancer in the British Journal of Cancer |
